Geneva Capital Management’s LeMaitre Vascular LMAT Stock Holding History

Geneva Capital Management’s Portfolio LMAT Stock Details LMAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$56.5M	Sell	589,064 -164,928	-22%	-$16.9M	1.3%	29
2026 Q1	$82.3M	Sell	753,992 -60,691	-7%	-$5.78M	1.75%	19
2025 Q4	$66.1M	Sell	814,683 -97,565	-11%	-$8.4M	1.24%	26
2025 Q3	$79.8M	Sell	912,248 -2,990	-0.3%	-$267K	1.37%	22
2025 Q2	$76M	Buy	915,238 +51,489	+6%	+$4.3M	1.27%	25
2025 Q1	$72.5M	Sell	863,749 -1,833	-0.2%	-$171K	1.35%	22
2024 Q4	$79.8M	Sell	865,582 -12,263	-1%	-$1.18M	1.38%	24
2024 Q3	$81.5M	Sell	877,845 -1,682	-0.2%	-$146K	1.36%	24
2024 Q2	$72.4M	Sell	879,527 -20,511	-2%	-$1.51M	1.32%	28
2024 Q1	$59.7M	Sell	900,038 -4,686	-0.5%	-$289K	1.05%	33
2023 Q4	$51.4M	Sell	904,724 -1,904	-0.2%	-$99.7K	0.97%	39
2023 Q3	$49.4M	Buy	906,628 +4,266	+0.5%	+$253K	1.04%	32
2023 Q2	$60.7M	Sell	902,362 -4,610	-0.5%	-$281K	1.2%	30
2023 Q1	$46.7M	Buy	906,972 +13,660	+2%	+$663K	0.95%	41
2022 Q4	$41.1M	Buy	893,312 +1,474	+0.2%	+$69K	0.92%	42
2022 Q3	$45.2M	Buy	891,838 +35,059	+4%	+$1.75M	1.04%	35
2022 Q2	$39M	Sell	856,779 -10,038	-1%	-$449K	0.9%	45
2022 Q1	$40.3M	Sell	866,817 -9,890	-1%	-$443K	0.78%	54
2021 Q4	$44M	Sell	876,707 -20,189	-2%	-$1.04M	0.71%	59
2021 Q3	$47.6M	Sell	896,896 -6,826	-0.8%	-$384K	0.81%	53
2021 Q2	$55.1M	Sell	903,722 -15,853	-2%	-$842K	0.9%	42
2021 Q1	$44.9M	Sell	919,575 -22,056	-2%	-$1.03M	0.77%	54
2020 Q4	$38.1M	Buy	941,631 +26,583	+3%	+$950K	0.65%	64
2020 Q3	$29.8M	Buy	915,048 +23,156	+3%	+$695K	0.61%	71
2020 Q2	$23.5M	Buy	891,892 +22,551	+3%	+$590K	0.51%	76
2020 Q1	$21.7M	Buy	+869,341	New	+$26.8M	0.62%	69

Other funds holding LMAT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geneva Capital Management's LMAT Position: Q2 2026 in Review

Geneva Capital Management reduced its LeMaitre Vascular (LMAT) stake by 22% in Q2 2026, selling an estimated $16.9M and leaving 589,064 shares worth $56.5M. The position accounts for 1.3% of the portfolio, ranked #29.

Geneva Capital Management first reported a position in LMAT in Q1 2020 and has held it in 26 quarters since. The position peaked at $82.3M in Q1 2026. 326 funds tracked by Wall St. Rank hold LMAT as of Q2 2026.

Geneva Capital Management held 589,064 shares of LeMaitre Vascular worth $56.5M as of Q2 2026.
Geneva Capital Management sold 164,928 LeMaitre Vascular shares in Q2 2026, an estimated $16.9M.
LeMaitre Vascular made up 1.3% of Geneva Capital Management's portfolio in Q2 2026, its #29 holding.
Geneva Capital Management first reported a position in LeMaitre Vascular in Q1 2020 and has held it in 26 quarters since.
Geneva Capital Management's LeMaitre Vascular position peaked at $82.3M in Q1 2026.
326 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q2 2026.

Based on Geneva Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.